α-硫辛酸和前列地尔联合治疗2型糖尿病周围神经病变患者的临床效果及对其运动神经传导速度和感觉神经传导速度的影响被引量：10

Clinical Effects of Alpha-Lipoic Acid and Prostaglandin on Motor Nerve Conduction Velocity and Sensory Nerve Conduction Velocity in Patients with Type 2 Diabetes Mellitus Complicated with Peripheral Neuropathy

在线阅读下载PDF

导出

摘要目的探讨α-硫辛酸和前列地尔联合治疗2型糖尿病周围神经病变患者的效果及对其运动神经传导速度和感觉神经传导速度的影响。方法选取2016年1月至2017年1月于中国科学院大学深圳医院(光明)内分泌科治疗的2型糖尿病周围神经病变患者168例作为研究对象,随机分为A、B、C3组,每组56例,分别采用α-硫辛酸、前列地尔和两者联合用药治疗。比较3组患者治疗前后视觉模拟评分法(VAS)评分、多伦多临床评分系统(TCSS)评分,治疗后正中神经和腓神经的运动神经传导速度和感觉神经传导速度以及临床效果。结果治疗后,3组患者VAS及TCSS评分均明显下降,C组VAS、TCSS评分均明显低于A、B两组,差异有统计学意义(P<0.05);治疗后C组患者的正中神经、腓神经的运动神经传导速度和感觉神经传导速度均显著高于A、B两组,且C组的临床治疗有效率明显高于A、B两组,差异有统计学意义(P<0.05)。结论在治疗2型糖尿病周围神经病变患者时,α-硫辛酸和前列地尔联合治疗临床效果显著,能有效改善其运动和感觉神经传导速度。 Objective To exlpore the effects of alpha-lipoic acid and prostaglandin in the treatment of type 2 diabetes mellitus patients with peripheral neuropathy and its influence on motor and sensory nerve conduction velocities. Methods A total of 168 patients with type 2 diabetes mellitus complicated with peripheral neuropathy treated in the Department of Endocrinology, Shenzhen Hospital, Chinese Academy of Sciences(Guangming) from January 2016 to January 2017 were randomly divided into 3 groups: A, B and C, with 56 patients in each group, treated with alpha-lipoic acid, alprostadil and their combination. The visual analogue scale(VAS) score and Toronto clinical score system(TCSS) score before and after treatment, the motor nerve conduction velocity and sensory nerve conduction velocity of median nerve and peroneal nerve after treatment were compared among the 3 groups. Results After treatment, the VAS and TCSS scores of the 3 groups were significantly decreased, and the VAS and TCSS scores of group C were significantly lower than those of group A and B(P<0.05). After treatment, the motor nerve conduction velocity and sensory nerve conduction velocity of median nerve and peroneal nerve of group C were significantly higher than those of group A and B, and curative rate of the clinical treatment of group C was significantly higher than that of A and B groups(P<0.05). Conclusion In the treatment of type 2 diabetes mellitus patients with peripheral neuropathy, the combination of alpha-lipoic acid and alprostadil has a significant clinical effects and can effectively improve the motor and sensory nerve conduction velocity.

作者魏照星李强罗江秀钟超 WEI Zhao-Xing;LI Qiang;LUO Jiang-Xiu;ZHONG Chao(Shenzhen Hospital,Chinese Academy of Sciences(Guangming),Shenzhen 518106,China)

机构地区中国科学院大学深圳医院(光明)

出处《中国药物经济学》 2019年第11期117-119,125,共4页 China Journal of Pharmaceutical Economics

关键词 Α-硫辛酸前列地尔 2型糖尿病周围神经病变临床疗效神经传导速度 Alpha-lipoic acid Alprostadil Type 2 diabetes mellitus Peripheral neuropathy Clinical efficacy Nerve conduction velocity

分类号 R587.2 [医药卫生—内分泌] R971 [医药卫生—药品]

作者简介通信作者:魏照星,E-mail:diidooo@163.com。

引文网络
相关文献

参考文献9

1周海平.前列地尔联合α-硫辛酸干预糖尿病周围神经病变的效果研究[J].中国医药指南,2019,17(18):129-130. 被引量：3
2张俊蓉.硫辛酸联合前列地尔治疗2型糖尿病周围神经病变的临床疗效和安全性分析[J].中国药物与临床,2019,19(4):585-587. 被引量：19
3路强,陈国丽.硫辛酸联合前列地尔治疗2型糖尿病早期下肢血管神经病变疗效观察[J].双足与保健,2017,26(12):87-88. 被引量：3
4常杰.老年2型糖尿病周围神经病变患者治疗策略的研究[J].中国社区医师,2016,32(35):40-42. 被引量：1
5卢恋真.肌电图检查在老年2型糖尿病合并周围神经病变患者中的诊断价值分析[J].四川解剖学杂志,2019,0(2):72-73. 被引量：8
6郝国华,曹思明,翁文采.2型糖尿病患者并发糖尿病周围神经病变的影响因素[J].广西医学,2018,40(6):633-635. 被引量：20
7毛春谱,张晓乐,刘春燕,蔡文婷,张红梅.α-硫辛酸联合前列地尔对糖尿病周围神经病变患者血清炎症因子及神经传导速度的影响[J].现代生物医学进展,2018,18(23):4497-4501. 被引量：10
8杨昕,刘志民.前列地尔联合α-硫辛酸及甲钴胺治疗初诊2型糖尿病周围神经病变疗效观察[J].中国药业,2016,25(19):13-16. 被引量：37
9王艳红,岳宗相,黄荣利,钟振东,谢春光.前列地尔联合α-硫辛酸治疗糖尿病周围神经病变的临床研究[J].检验医学与临床,2016,13(15):2097-2099. 被引量：34

二级参考文献102

1Petit Jr WA, Upender RP. Medical evaluation and treatment of diabetic peripheral neuropathy[J]. Clin Podiatr Med Surg, 2003,20 (4) : 671-688.
2Lavery LA, Wunderlich RP, Tredwell JL. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations[J]. Diabetes Res Clin Pract, 2005,70 ( 1 ) : 31-37.
3Rosen P,Nawroth PP,King G,et al. The role of oxidative stress in the onset and progression of diabetes and its complications[-J~. Diabetes Metab Res Rev, 2001,17 ( 3 ) : 189-212.
4Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome[J]. Arch Gynecol Obstet, 2010,281 (6) : 10091014.
5Williams MD, Nadle JL. Inflammatory mechanisms of dia - betic complications [J]. Curr Diab Rep,2007 ,7(3):242-248.
6Vileikyte L, Peyrot M, Gonzalez JS, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longi- tudinalstudy[J]. Diabetologia,2009,52:1265-1273.
7Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: up- date on definitions,diagnontic criteria, estimation of severity, and treatments[J]. Diabetes Care,2010,33:2285-2293.
8Solomon Tesfaye. Advances in the management of diabetic periph- eral neuropathy [J]. Current Opinion in Supportive & Palliative Care, 2009,3(2):136-143.
9Tesfaye S,Boulton AJ. Diabetic Neuropathy[M]. Oxford: Oxford University Press,2009:34.
10KoIla VK, Madhavia G, Pulla Reddy B, et al. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian pa- tients with type 2 diabetes[J]. Cytokine, 2009, 47(3):173-177.